



# **Administration of Nuvaxovid (Novavax COVID-19 Vaccine (recombinant, adjuvanted)) Vaccine**

**Patient group direction (PGD) template**

date: 13 March 2023



Translations



Easy read



BSL



Audio



Large print



Braille

Translations and other formats are available on request at:

@ [p hs.otherformats@p hs.scot](mailto:p hs.otherformats@p hs.scot)

☎ 0131 314 5300

Public Health Scotland is Scotland's national agency for improving and protecting the health and wellbeing of Scotland's people.

© Public Health Scotland 2023



This publication is licensed for re-use under the [Open Government Licence v3.0](#).

For more information, visit  
[www.publichealthscotland.scot/ogl](http://www.publichealthscotland.scot/ogl)

[www.publichealthscotland.scot](http://www.publichealthscotland.scot)

## Most recent changes

Version	Date	Summary of changes
1.2	13 March 2023	<ul style="list-style-type: none"> <li>• Exclusion criteria updated to remove influenza vaccine in the previous 7 days</li> <li>• Cautions section updated – updated wording on co-administration with other vaccines to align with updated Green Book chapter</li> <li>• Cautions section updated – minor changes to pregnancy and breast feeding section</li> <li>• Cautions section updated – updated wording on past history of COVID-19 infection to align with updated Green Book chapter</li> <li>• Action if excluded section updated to remove recent COVID test</li> <li>• Frequency section updated – section on severe immunosuppression updated to align with updated Green Book chapter</li> <li>• Frequency section updated – section on reinforcing vaccine (interval) updated to align with updated Green Book chapter</li> <li>• Advice to patient section updated to remove avoiding influenza vaccine for seven days</li> <li>• Use out with SmPC section updated to align with Green Book chapter advice on observation after vaccination</li> <li>• Use out with SmPC section updated to include off label use as a booster from age 12 years.</li> <li>• Storage section updated to align with updated storage instructions.</li> <li>• Observation following vaccination section updated to align with Green Book chapter advice on observation after vaccination</li> </ul>

## Contents

Most recent changes	1
Authorisation	3
1. Clinical situation	4
2. Description of treatment	11
3. Adverse reactions	19
4. Characteristics of staff authorised under the PGD	23
5. Audit trail	26
6. Additional references	27
7. PGD for administration of Nuvaxovid (Novavax COVID-19 Vaccine (recombinant, adjuvanted)) PGD V1.2 (valid from 13 March 2023 and expires 31 March 2024): authorisation	28
8. Version history	30

## Authorisation

### PGD Nuvaxovid (Novavax COVID-19 Vaccine (recombinant, adjuvanted))

#### Vaccine

This specimen Patient Group Direction (PGD) template has been produced by Public Health Scotland to assist NHS Boards. NHS Boards should ensure that the final PGD is considered and approved in line with local clinical governance arrangements for PGDs.

The qualified health professionals who may administer Nuvaxovid (Novavax COVID-19 Vaccine (recombinant, adjuvanted)) under this PGD can only do so as named individuals. It is the responsibility of each professional to practice within the bounds of their own competence and in accordance with their own Code of Professional Conduct and to ensure familiarity with the manufacturer's product information/Summary of Product Characteristics (SmPC) for all vaccines administered in accordance with this PGD. NHS Board governance arrangements will indicate how records of staff authorised to operate this PGD will be maintained. Under PGD legislation there can be no delegation. Administration of the vaccine has to be by the same practitioner who has assessed the patient under the PGD.

This PGD has been produced for NHS ..... by:

Doctor (Name / Signature).....

Pharmacist (Name /Signature) .....

Nurse (Name / Signature) .....

Approved on behalf of NHS..... by:

Medical Director (Name / Signature) .....

Director of Pharmacy/Senior Pharmacist (Name / Signature) .....

Clinical Governance Lead (Name / Signature) .....

Date approved: .....

Effective from: 13 March 2023

Review date: 31 March 2024

# 1. Clinical situation

## 1.1. Indication

Nuvaxovid (Novavax COVID-19 vaccine (recombinant, adjuvanted)) vaccine is indicated for active immunisation against COVID-19 disease caused by SARS-CoV-2 virus in accordance with Scottish Government COVID-19 immunisation programme, JCVI advice/recommendations given in Green Book **Chapter 14a** and subsequent correspondence/publications from Scottish Government.

## 1.2. Inclusion criteria

Nuvaxovid (Novavax COVID-19 vaccine (recombinant, adjuvanted)) vaccine should be offered in accordance with the recommendations in Green Book **Chapter 14a**.

National policy must be followed in relation to the priority groups eligible for vaccination at a particular point in time.

Valid consent has been given to receive the vaccine.

## 1.3. Exclusion criteria

Individuals who:

- have had a confirmed anaphylactic reaction to a previous dose of any COVID-19 vaccine.
- have had a confirmed anaphylactic reaction to any component of the vaccine or residual products from manufacture. Practitioners must check the marketing authorisation holder's SmPC for details of vaccine components.
- are under 12 years of age.

- have evidence of current deterioration of COVID-19 symptoms; deferral of vaccination may be considered to avoid incorrect attribution of any change in the person's underlying condition to the vaccine.
- are suffering from acute severe febrile illness (the presence of a minor infection is not a contraindication for immunisation).
- are bone marrow and peripheral blood stem cell donors who have commenced GCSF; the vaccination (first or second dose) must be delayed at least until 72 hours after stem cell collection (both peripheral blood stem cell and bone marrow donation). This is a precautionary advice to avoid vaccination when receiving Granulocyte-colony stimulating factor (GCSF) and allow for post donation recovery period.
- developed myocarditis or pericarditis following a previous dose of COVID-19 vaccination.

#### **1.4. Cautions/need for further advice/ circumstances when further advice should be sought from a doctor**

The Green Book, COVID-19 **chapter 14a** advises that there are very few individuals who cannot receive COVID-19 vaccines. Where there is doubt, rather than withholding vaccination, appropriate advice should be sought from the relevant specialist, or from the local immunisation or health protection team.

##### **Individuals with a history of allergy**

Those with a personal history of allergy should be managed in line with Green Book **Chapter 14a**, table 5.

Where individuals have experienced a possible allergic reaction to a dose of COVID-19 vaccine, follow the guidance in the flowchart in Green Book **Chapter 14a** in relation to administration of subsequent doses.

Green Book **Chapter 14a** states individuals with non-allergic reactions (vasovagal episodes, non-urticarial skin reaction or non-specific symptoms) to the first dose of a COVID-19 vaccine can receive the second dose of vaccine in any vaccination setting. Observation for 15 minutes is recommended.

A longer observation period when indicated after clinical assessment in individuals with a history of allergy as set out in Green Book **Chapter 14a**, table 5 and flowchart.

No specific management is required for individuals with a family history of allergies.

### Individuals with thrombocytopenia

Guidance produced by the UK ITP Forum Working Party advises discussing the potential for a fall in platelet count in patients with a history of immune thrombocytopenia (ITP) receiving any COVID-19 vaccine and recommends a platelet count check 2-5 days after vaccination.

### Guillain-Barré syndrome (GBS)

Very rare reports have been received of GBS following COVID-19 vaccination.. Individuals who have a history of GBS should be vaccinated as recommended for their age and underlying risk status. In those who are diagnosed with GBS after the first dose of vaccine, the balance of risk benefit is in favour of completing a full COVID-19 vaccination schedule. Where GBS occurs following either of the mRNA vaccines, further vaccination can proceed as normal, once recovered.

### Individuals with a bleeding history

Individuals with a bleeding disorder may develop a haematoma at the injection site (see Route of Administration).

### Co-administration with other vaccines

The COVID-19 vaccines in use in the UK are considered inactivated, where individuals in an eligible cohort present having recently received another inactivated



or live vaccine, COVID-19 vaccination should still be given. The same applies for most other live and inactivated vaccines where COVID-19 vaccination has been received first or where a patient presents requiring two or more vaccines. It is generally better for vaccination to proceed to avoid any further delay in protection and to avoid the risk of the patient not returning for a later appointment. This includes but is not limited to vaccines commonly administered around the same time or in the same settings (inactivated influenza vaccine, pneumococcal polysaccharide vaccine, shingles vaccine, pertussis-containing vaccines in pregnancy and LAIV, HPV, MenACWY and Td-IPV vaccines in school age children ).

When administering at the same time as other vaccines, care should be taken to ensure that the appropriate route of injection is used for all the vaccinations. The vaccines should be given at separate sites, preferably in different limbs. If given in the same limb, they should be given at least 2.5cm apart. The site at which each vaccine was given should be noted in the individual's records.

## Syncope

Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.

## Pregnancy and breastfeeding

JCVI advise there is no known risk associated with giving these types of vaccines during pregnancy. These vaccines cannot replicate, so they cannot cause infection in either the woman or the unborn child.

Vaccination in pregnancy should be offered in accordance with recommendations in Green Book [Chapter 14a](#), following a discussion of the risks and benefits of vaccination with the woman.

Because of the wider experience with mRNA vaccines, these are currently the preferred vaccines to offer to pregnant women. For those under 18 years Comirnaty® (COVID-19 mRNA vaccine, Pfizer/BioNTech) is preferred. When mRNA vaccines are not considered clinically suitable, Nuvaxovid (Novavax COVID-19 vaccine (recombinant, adjuvanted)) vaccine may be used for primary vaccination of pregnant women, including to complete a course or as a booster, although experience in pregnancy is relatively limited.

If a woman finds out she is pregnant after she has started a course of vaccine, she should complete vaccination at the recommended interval.

There is no known risk associated with giving non-live vaccines whilst breastfeeding. JCVI advises that breastfeeding women may be offered any suitable COVID-19 vaccine. Emerging safety data is reassuring: mRNA was not detected in the breast milk of recently vaccinated and protective antibodies have been detected in breast milk. The developmental and health benefits of breastfeeding should be considered along with the woman's clinical need for immunisation against COVID-19.

## Clinical trial participants

Individuals who have participated in a clinical trial of either primary or booster COVID-19 vaccines should be provided with written advice on whether and when they should be safely vaccinated in the routine programme. Advice should also be provided from the trial investigators on whether any individual could receive additional doses for the purposes of vaccine certification. Trial participants who are eligible for boosters should be offered vaccination in line with the general population, at least three months after the dose considered as the final primary dose or the final revaccination (if the latter is required for certification purposes).

## Individuals with a past history of COVID-19 infection

There are no safety concerns from vaccinating with a past history of COVID-19 infection, or with detectable COVID-19 antibody.

Vaccination of individuals who may be infected or asymptomatic or incubating COVID-19 infection is unlikely to have a detrimental effect on the illness although individuals with suspected COVID-19 infection should not attend vaccination sessions to avoid infecting others.

As clinical deterioration can occur up to two weeks after infection vaccination should ideally be deferred until clinical recovery.

There is no need to defer immunisation in individuals after recovery from a recent episode with compatible symptoms, whether or not they are tested for COVID-19.

During care home outbreaks, vaccination of residents with confirmed COVID-19 may go ahead provided the residents are clinically stable and infection control procedures can be maintained.

### 1.5 Action if excluded

Specialist advice should be sought on the vaccine and circumstances under which it could be given as vaccination using a patient specific direction may be indicated. The risk to the individual of not being immunised must be taken into account.

Document the reason for exclusion and any action taken in accordance with local procedures.

Inform or refer to the clinician in charge.

In case of deferral due to COVID-19 symptoms advise when the individual can be vaccinated and how future vaccination may be accessed.

In case of postponement due to acute illness, advise when the individual can be vaccinated and ensure another appointment is arranged.

## **1.6. Action if patient declines**

Advise the individual/carer about the protective effects of the vaccine, the risks of infection and potential complications if not immunised.

Advise how future immunisation may be accessed if they subsequently decide to receive the COVID-19 vaccine.

Document advice given and decision reached.

Inform or refer to the clinician in charge.

## **2. Description of treatment**

### **2.1. Name of medicine/form/strength**

Nuvaxovid (COVID-19 Vaccine (recombinant, adjuvanted)) dispersion for injection.

Multidose vial which contains 10 doses of 0.5 ml.

One dose (0.5 ml) contains 5 micrograms of the SARS-CoV-2 spike protein and is adjuvanted with Matrix-M.

### **2.2. Route of administration**

Administer by intramuscular (IM) injection preferably into the deltoid area of the upper arm.

Each vial contains at least the number of doses stated. It is normal for liquid to remain in the vial after withdrawing the final dose.

Care should be taken to ensure a full 0.5 ml dose is administered. Where a full 0.5 ml dose cannot be extracted, the remaining volume should be discarded.

Individuals with bleeding disorders may be vaccinated intramuscularly if, in the opinion of a doctor familiar with individual's bleeding risk, vaccines or similar small volume intramuscular injections can be administered with reasonable safety by this route. If the individual receives medication/ treatment to reduce bleeding, for example treatment for haemophilia, intramuscular vaccination can be scheduled shortly after such medication/treatment is administered. Individuals on stable anticoagulation therapy, including individuals on warfarin who are up-to-date with their scheduled INR testing and whose latest INR is below the upper level of the therapeutic range, can receive intramuscular vaccination. A fine needle (23 or 25 gauge) should be used for the vaccination, followed by firm pressure applied to the site without rubbing for at least 2 minutes. The individual/parent/carer should be informed about the risk of haematoma from the injection.

The vaccine should be visually inspected for particulate matter and discoloration prior to administration. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.

## 2.3. Dosage

0.5ml

## 2.4. Frequency

### Primary immunisation

JCVI advise that a full dose mRNA vaccine is recommended for primary immunisation. When mRNA vaccines are not considered clinically suitable, Nuvaxovid (Novavax COVID-19 vaccine (recombinant, adjuvanted)) may be used for primary vaccination of adults and children aged 12 years old or older.

The course of Nuvaxovid (Novavax COVID-19 vaccine (recombinant, adjuvanted)) consists of two separate doses of 0.5ml each, a minimum of 21 days apart.

There is evidence of better immune response and/or protection where longer intervals between doses in the primary schedule are used.

Based on this evidence, longer intervals are likely to provide more durable protection. JCVI is currently recommending a minimum interval of eight weeks between doses of all the available COVID-19 vaccines where a two-dose primary schedule is used.

If an interval longer than the recommended interval is left between doses in the two dose primary schedule, the second dose should still be given. The course does not need to be restarted.

The main exception to the eight-week lower interval would be those about to commence immunosuppressive treatment. In these individuals, the minimal intervals outlined above may be followed to enable the vaccine to be given whilst their immune system is better able to respond.

Individuals who are about to receive planned immunosuppressive therapy should be considered for vaccination prior to commencing therapy (ideally at least two weeks before), when their immune system is better able to make a response. Where possible, it would also be preferable for the two-dose schedule to be completed prior to commencing immunosuppression. This would entail offering the second dose at the recommended minimum for that vaccine (three or four weeks from the first dose) to provide maximum benefit that may not be received if the second dose was given during the period of immunosuppression.

## 12 –15 years

Children and young people aged 12 to 15 years who are in recognised risk groups (as defined in Green Book [Chapter 14a](#)) or who expect to share living accommodation on most days (and therefore for whom continuing close contact is unavoidable) with individuals of any age who are immunosuppressed (as defined in Green Book [Chapter 14a](#)) should receive two 0.5ml doses of vaccine at an interval of at least eight weeks.

For children and young people aged 12 to 15 years who are not in a risk group or share living accommodation on most days with individuals of any age who are immunosuppressed JCVI have now recommended that a second dose of vaccine should be offered after an interval of 12 weeks. This interval reflects the strong evidence of high levels of protection against severe disease from the first dose, although could be shortened to eight weeks when rapid protection is required, for example in periods of high incidence or circulation of a new variant in a vulnerable population.

## 16-17 years

Young people aged 16 to 17 years who are in a recognised clinical risk group (as defined in COVID-19 chapter of Green Book) and those who work in health and social care should receive two 0.5ml doses of vaccine at an interval of at least eight weeks. This includes those aged 16 to 17 years who expect to share living accommodation on most days (and therefore for whom continuing close contact is

unavoidable) with individuals of any age who are immunosuppressed (as defined in Green Book [Chapter 14a](#)).

Initially JCVI advised that young people aged 16-17 years who are not in a risk group should receive their first dose of vaccine. A second dose of vaccine is now offered at an interval of 12 weeks. This longer interval in this age group reflects the strong evidence of high levels of protection against severe disease from the first dose, although could be shortened to eight weeks when rapid protection is required, for example in periods of high incidence or circulation of a new variant in a vulnerable population. Emerging evidence also suggests that countries with longer schedules (eight to twelve weeks) may have a lower rate of myocarditis after the second dose. Although this latter evidence is limited, JCVI have taken a precautionary approach to mitigate the very rare risk of post-vaccine myocarditis. Young people should be fully informed about the benefits and risks of the second dose and able to discuss the optimal timing for them.

## Severe immunosuppression

For those identified as meeting the definition for severe immunosuppression (as defined in Green Book [Chapter 14a](#)) in proximity of their first or second vaccine doses in the primary schedule, in line with specialist advice, a third primary dose should be offered. The third primary dose should be given at least 8 weeks after the second dose.

In general, vaccines administered during periods of minimum immunosuppression are more likely to generate better immune responses. Therefore, any additional doses should ideally be given with special attention paid to current or planned immunosuppressive therapies. For example:

- where possible, third primary or additional booster doses should be delayed until two weeks after the period of immunosuppression, in addition to the time period for clearance of the therapeutic agent
- alternatively, consideration should be given to vaccination during a treatment 'holiday' or when the degree of immunosuppression is at a minimum



Any decision to defer immunosuppressive therapy or to delay possible benefit from vaccination until after immunosuppressive therapy should only be taken after due consideration of the risks of exacerbating their underlying condition, as well as the risks from COVID-19.

When mRNA vaccines are not considered clinically suitable, Novavax COVID-19 vaccine may be used for vaccination of individuals from 12 years of age.

## Reinforcing vaccination

A single dose of Nuvaxovid (Novavax COVID-19 vaccine (recombinant, adjuvanted)) may be offered as a booster to those aged 12 years and over and defined as eligible in Green Book **Chapter 14a** who have received primary immunisation (and previous boosters) and in whom mRNA vaccines are not clinically suitable.

Boosters should be offered around six months from the previous dose, but can be given three months (12 weeks) from the previous dose (regardless of the vaccine given for the previous dose).

## 2.5. Duration of treatment

See frequency section.

## 2.6. Maximum or minimum treatment period

See frequency section.

## 2.7. Quantity to supply/administer

See frequency section.

## 2.8. ▼ black triangle medicines

Yes.

Nuvaxovid (Novavax COVID-19 vaccine (recombinant, adjuvanted)) is subject to additional monitoring and has been designated ▼

Healthcare professionals and individuals/carers should report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on <http://www.mhra.gov.uk/yellowcard>.

## 2.9. Legal category

Prescription only medicine (POM).

## 2.10. Is the use out with the SmPC?

The vaccine marketing authorisation holder's summary of product characteristics states that the vaccine should be given as a series of two doses (0.5ml, each) 21 days apart and does not contain any provision for third primary or booster doses. Hence third primary or booster doses are considered 'off - label'.

This is superseded by the JCVI recommendation of a minimum interval of eight weeks between doses of all the available COVID-19 vaccines where a two-dose primary schedule is used, for third primary and for use of the vaccine as a booster when mRNA vaccines are not considered clinically suitable.

The vaccine marketing authorisation holder's SmPC states that the vaccine should be given as a booster from age 18 years. This is superseded by the JCVI set out in Green Book **Chapter 14a** that the vaccine may be used as a booster from age 12 years when mRNA vaccines are clinically unsuitable.

The vaccine marketing authorisation holder's SmPC states that close observation for at least 15 minutes is recommended following vaccination. In recognition of the need to accelerate delivery of the programme in response to the emergence of the Omicron variant, the UK Chief Medical Officers recommended temporary suspension of this requirement. This temporary suspension in individuals without a history of allergy was also agreed by the Commission on Human Medicines. The advice to suspend the routine 15 minute observation period applies to all the currently

available COVID-19 vaccines, including the bivalent mRNA products and both the Novavax and Sanofi vaccines.

Where a vaccine is recommended off-label consider, as part of the consent process, informing the individual/parent/carer that the vaccine is being offered in accordance with national guidance but that this is outside the product licence.

Vaccine should be stored according to the conditions detailed in the Storage section below. However, in the event of an inadvertent or unavoidable deviation of these conditions refer to National Vaccine Incident Guidance. Where vaccine is assessed in accordance with these guidelines as appropriate for continued use this would constitute off-label administration under this PGD.

## **2.11. Storage requirements**

Vaccine should be stored at a temperature of +2° to +8°C.

Store in the original packaging to protect from light.

Do not freeze.

NHS Board guidance on Storage and Handling of vaccines should be observed.

In the event of an inadvertent or unavoidable deviation of these conditions, vaccine that has been stored outside the conditions stated above should be quarantined and risk assessed for suitability of continued use or appropriate disposal.

Chemical and physical in-use stability has been demonstrated for 12 hours at 2°C to 8°C or 6 hours at room temperature (maximum 25°C) from the time of first needle puncture to administration.

The vaccine vial has space to write the date and time that the vial should be discarded following first puncture; write this on the vial label.

## **2.12. Additional information**

Minor illnesses without fever or systemic upset are not valid reasons to postpone immunisation. If an individual is acutely unwell, immunisation may be postponed until they have fully recovered.

There is no convincing evidence of any safety concerns from vaccinating individuals with a past history of COVID-19 infection, or with detectable COVID-19 antibody.

Having prolonged COVID-19 symptoms is not a contraindication to receiving COVID-19 vaccine but if the patient is seriously debilitated, still under active investigation, or has evidence of recent deterioration, deferral of vaccination may be considered to avoid incorrect attribution of any change in the person's underlying condition to the vaccine.

## **3. Adverse reactions**

### **3.1. Warnings including possible adverse reactions and management of these**

Side effects after the vaccine are similar to other COVID-19 vaccines, with slightly lower rates of local reactions and systemic effects when compared to mRNA vaccines. Around 50% of dose 1 and 70% of dose 2 recipients reporting pain and /or tenderness at the injection site and around 40-50% reporting systemic symptoms including fatigue, malaise, headache and muscle pain, with rates of fever below 10%. Overall, there was a higher incidence of adverse reactions in younger age group (18-64 years).

Small numbers of cases of myocarditis or pericarditis were reported across the trials and in post-marketing follow up. Myocarditis and pericarditis have now been added to the list of side effects after the vaccine.

For full details/information on possible side effects, refer to the marketing authorisation holder's SmPC.

As with all vaccines there is a very small possibility of anaphylaxis and facilities for its management must be available.

In the event of severe adverse reaction individuals should be advised to seek medical advice.

### **3.2. Reporting procedure for adverse reactions**

Healthcare professionals and individuals/carers should report all suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on <http://www.mhra.gov.uk/yellowcard>.

Any adverse reaction to a vaccine should be documented in accordance with locally agreed procedures in the individual's record and the individual's GP should be informed.

Programmatic Adverse Events should be recorded in line with local procedures and where appropriate escalated in accordance with the national framework.

### **3.3. Advice to patient or carer including written information**

Written information to be given to individuals:

- Provide manufacturer's consumer information leaflet/patient information leaflet (PIL) provided with the vaccine.
- Provide copy of Public Health Scotland post-vaccination leaflet.
- Provide copy of Pregnant, planning a pregnancy or breastfeeding, a guide to COVID-19 vaccine to women of child bearing years.

Individual advice / follow up treatment:

- Inform the individual/carers of possible side effects and their management.
- Vaccinated individuals should be advised that it is common to develop a fever after vaccination and that this normally happens within 48 hours after the vaccination and usually goes away within 48 hours. This is a common, expected reaction, and self-isolation and testing for COVID-19 are not required.
- Vaccinated individuals should be advised that if the fever started 48 hours after the vaccination or lasts longer than 48 hours, they should seek medical advice as they may have COVID-19 or another infection.
- Vaccinated individuals should be advised that feeling generally unwell, shivery, achy and tired were also symptoms commonly reported by vaccine recipients in the clinical trials. Generally, these symptoms were found to resolve within one to two days without treatment, but paracetamol can be taken if necessary to relieve any of these symptoms.
- Inform the individual/carers that anyone who has any of the following symptoms after vaccination should seek medical advice urgently:

- chest pain
- shortness of breath
- feelings of having a fast-beating, fluttering, or pounding heart
- As has always been recommended, any fever after vaccination should be monitored and if individuals are concerned about their health at any time, they should seek advice from their GP or NHS24.
- The individual should be advised to seek medical advice in the event of a severe adverse reaction.
- Inform the individual that they can report suspected adverse reactions to the MHRA using the Yellow Card reporting scheme on:  
<http://www.mhra.gov.uk/yellowcard>
- Immunosuppressed individuals should be advised that they may not make a full immune response to the vaccine and they should continue to take appropriate measures to protect themselves against this infection.
- When administration is postponed advise the individual how future vaccination may be accessed.
- When applicable, advise the individual/carer when to return for vaccination or when a subsequent vaccine dose is due.

### 3.4. Observation following vaccination

Following COVID-19 vaccine administration, individuals should be observed for any immediate reactions whilst they are receiving any verbal post vaccination information and exiting the centre.

According to the SmPC, it is recommended that all recipients of the Pfizer BioNTech, Moderna, Novavax and Sanofi vaccines are kept for observation and monitored for a minimum of 15 minutes. In recognition of the need to accelerate delivery of the programme in response to the emergence of the Omicron variant, the UK Chief

Medical Officers recommended suspension of this requirement for the two mRNA vaccines (Comirnaty and Spikevax) in both adults and children. This temporary suspension in individuals without a history of allergy was also agreed by the Commission on Human Medicines. The advice to suspend the routine 15 minute observation period applies to all the currently available COVID-19 vaccines, including the bivalent mRNA products and both the Novavax and Sanofi vaccines.

The Scottish Government has made further recommendations that all doses of COVID-19 vaccines be followed by a 5 minute observation period.

A longer observation period when indicated after clinical assessment in individuals with a history of allergy as set out in Green Book [Chapter 14a](#), Table 5 and flowchart.

As syncope (fainting) can occur following vaccination, all vaccinees should either be driven by someone else or should not drive for 15 minutes after vaccination.

### **3.5. Follow up**

As above.

### **3.6. Additional facilities**

A protocol for the management of anaphylaxis and an anaphylaxis pack must always be available whenever vaccines are given. Immediate treatment should include early treatment with intramuscular adrenaline, with an early call for help and further IM adrenaline every 5 minutes.

The health professionals overseeing the immunisation service must be trained to recognise an anaphylactic reaction and be familiar with techniques for resuscitation of a patient with anaphylaxis.



## **4. Characteristics of staff authorised under the PGD**

### **4.1. Professional qualifications**

The following classes of registered healthcare practitioners are permitted to administer this vaccine:

- nurses and midwives currently registered with the Nursing and Midwifery Council (NMC)
- pharmacists currently registered with the General Pharmaceutical Council (GPhC)
- chiropodists/podiatrists, dieticians, occupational therapists, orthoptists, orthotists/prosthetists, paramedics, physiotherapists, radiographers and speech and language therapists currently registered with the Health and Care Professions Council (HCPC)
- dental hygienists and dental therapists registered with the General Dental Council
- optometrists registered with the General Optical Council.

### **4.2. Specialist competencies or qualifications**

Persons must only work under this PGD where they are competent to do so.

All practitioners operating this PGD:

- demonstrate appropriate knowledge and skills to work under the PGD for the administration of COVID-19 vaccine.
- have met the requirements of the NES Proficiency document -COVID-19 vaccine administration for registered staff or the NES Proficiency document – COVID-19 vaccine administration. This NES Proficiency document can be

found at TURAS Learn at:

<https://learn.nes.nhs.scot/37676/immunisation/covid-19-vaccines>

All persons operating this PGD:

- must be authorised by name by their employer as an approved person under the current terms of this PGD before working to it.
- must be familiar with the vaccine product and alert to changes in the manufacturer's product information/ SmPC information.
- must be competent to undertake immunisation and to discuss issues related to immunisation to assess patients for vaccination and obtain consent.
- must be competent in the correct storage of vaccines and management of the cold chain if receiving, responsible for, or handling the vaccine.
- must be competent in the recognition and management of anaphylaxis or under the supervision of persons able to respond appropriately to immediate adverse reactions.
- must have access to the PGD and associated online resources.
- should fulfil any additional requirements defined by local policy.

All practitioners operating under the PGD are responsible for ensuring they remain up to date with the use of COVID-19 vaccines included. If any training needs are identified these should be discussed with the individuals in the organisation responsible for authorising individuals to act under the PGD.

## **Employer**

The employer is responsible for ensuring that persons have the required knowledge and skills to safely deliver the activity they are employed to provide under this PGD.

As a minimum, competence requirements stipulated in the PGD must be adhered to.

### **4.3. Continuing education and training**

All practitioners operating under the PGD are responsible for ensuring they remain up to date with the use of vaccines included. If any training needs are identified these should be discussed with the individuals in the organisation responsible for authorising individuals to act under this PGD.

## 5. Audit trail

### Record the following information:

- valid informed consent was given
- name of individual, address, date of birth and GP with whom the individual is registered if possible
- name of person that undertook assessment of individual's clinical suitability and subsequently administered the vaccine
- name and brand of vaccine
- date of administration
- dose, form and route of administration of vaccine
- batch number
- where possible expiry date
- anatomical site of vaccination
- advice given, including advice given if excluded or declines immunisation
- details of any adverse drug reactions and actions taken
- administered under PGD

Records should be kept in line with local procedures.

Local policy should be followed to encourage information sharing with the individual's General Practice.

All records should be clear, legible and contemporaneous and in an easily retrievable format.

## 6. Additional references

Practitioners operating the PGD must be familiar with:

- **Immunisation against Infectious Disease [Green Book]**
- **Immunisation against Infectious Disease [Green Book] COVID-19 chapter 14a**
- **Manufacturer's product information/ Summary of Product Characteristics**
- **Educational resources for registered professionals produced by National Education for Scotland**
- All relevant JCVI statements related to COVID-19 vaccination.
- All relevant Scottish Government advice including the relevant CMO letter(s)

## 7. PGD for administration of Nuvaxovid (Novavax COVID-19 Vaccine (recombinant, adjuvanted)) PGD V1.2 (valid from 13 March 2023 and expires 31 March 2024): authorisation

### Practitioner

This PGD does not remove professional obligations and accountability. It is the responsibility of each professional to practice within the bounds of their own competence and in accordance with their Code of Professional Conduct and to ensure familiarity with the marketing authorisation holder's summary of product characteristics for all vaccines administered in accordance with this PGD.

By signing this Patient Group Direction, you are indicating that you agree to its contents and that you will work within it. I agree to administer Nuvaxovid (Novavax COVID-19 Vaccine (recombinant, adjuvanted)) vaccine only in accordance with this PGD.

Name of professional	Signature	Date

## Authorising manager

I confirm that the practitioners named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of **[insert name of organisation]** for the above-named health care professionals who have signed the PGD to work under it.

Lead clinician for the service area:

Name .....

Signature .....

Date .....

Authorised staff should be provided with an individual copy of the clinical content of the PGD and a photocopy of the document showing their authorisation.

This authorisation sheet should be retained to serve as a record of those practitioners authorised to work under this PGD.

## 8. Version history

Version	Date	Summary of changes
1.0	22 August 2021	Version 1.0 new PGD
1.1	27 September 2021	<ul style="list-style-type: none"> <li>• Exclusion section updated to exclude those from age 12 years.</li> <li>• Cautions section on those Individuals with a past history of COVID-19 infection to include advice on high-risk children.</li> <li>• Frequency section updated to include those from age 12 years.</li> <li>• Warning section updated to align with Green Book wording on myocarditis and pericarditis.</li> <li>• Advice to patient section updated to advise not to have a flu vaccine in the 7 days following vaccination with Nuvaxovid (Novavax COVID-19 vaccine recombinant, adjuvanted).</li> </ul>
1.2	13 March 2023	<ul style="list-style-type: none"> <li>• Exclusion criteria updated to remove influenza vaccine in the previous 7 days</li> <li>• Cautions section updated – updated wording on co-administration with other vaccines to align with updated Green Book chapter</li> <li>• Cautions section updated – minor changes to pregnancy and breast feeding section</li> <li>• Cautions section updated – updated wording on past history of COVID-19 infection to align with updated Green Book chapter</li> <li>• Action if excluded section updated to remove recent COVID test</li> <li>• Frequency section updated – section on severe immunosuppression updated to align with updated Green Book chapter</li> <li>• Frequency section updated – section on reinforcing vaccine (interval) updated to align with updated Green Book chapter</li> <li>• Advice to patient section updated to remove avoiding influenza vaccine for seven days</li> </ul>



Version	Date	Summary of changes
		<ul style="list-style-type: none"> <li>• Use out with SmPC section updated to align with Green Book chapter advice on observation after vaccination</li> <li>• Use out with SmPC section updated to include off label use as a booster from age 12 years.</li> <li>• Storage section updated to align with updated storage instructions.</li> <li>• Observation following vaccination section updated to align with Green Book chapter advice on observation after vaccination</li> </ul>